# US 12,224,041 B2 · Assay for hemoglobin a (HBA) detection and genotyping

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,224,041 B2
- Document ID: US12224041B2
- Status: Granted
- Kind: B2
- Application number: 17/193,629
- Filed: 2021-03-05
- Published: 2021-09-09
- Granted: 2025-02-11
- Earliest claimed: 2020-03-06
- Assignees: Laboratory Corporation of America Holdings
- Applicants: Laboratory Corporation of America Holdings
- Inventors: Andrew Walker; Matt Robinson
- Web page: https://patentgrep.com/patent/US12224041B2

## CPC

- G16B 20/10: Ploidy or copy number detection
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 27/44782: {of a plurality of samples}
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- C12Q 2600/156: Polymorphic or mutational markers
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are techniques for implementation of a Hemoglobin A (HBA) assay and an HBA genotyping decision tree matrix in clinical testing. Particularly, aspects are directed to obtaining raw data from the HBA assay performed on a plurality of samples, calculating a first set of probe ratios for each sample based on the raw data, identifying a number of reference samples to be combined as a synthetic reference sample based on the first set of probe ratios, calculating a second set of probe ratios for each sample of the plurality of samples based on the raw data and the synthetic reference sample, and determining, by the decision tree matrix, an HBA genotype for each sample based on the second set of probe ratios for each sample and copy number calling thresholds for sample probe/reference probe ratios associated with each probe of the plurality of probes.

## Claims

### Claim 1

A computer-implemented method comprising:
obtaining nucleic acid from a plurality of samples;
performing a Hemoglobin A (HBA) assay on the nucleic acid to obtain raw data, wherein the HBA assay is performed using a plurality of probes capable of detection of copy number losses or gains in an α-globin gene cluster region of each sample of the plurality of samples, and the raw data comprises HBA copy number data for the plurality of probes;
selecting, by a computing system, a reference sample from the plurality of samples, wherein the reference sample is selected based on variability among the plurality of probes and a determination of an absence of a copy number variation based on the raw data for the plurality of probes for the reference sample;
calculating, by the computing system, a first set of probe ratios for each sample of the plurality of samples based on the raw data from the HBA assay and the reference sample;
identifying, by the computing system, a predetermined number of reference samples to be combined as a synthetic reference sample for the plurality of samples based on the first set of probe ratios;
generating, by the computing system, a list of the predetermined number of reference samples;
generating, by the computing system, the synthetic reference sample as a concatenation of the predetermined number of reference samples in the list;
calculating, by the computing system, a second set of probe ratios for each sample of the plurality of samples based on the raw data from the HBA assay and the synthetic reference sample;
iteratively inputting, by the computing system, the second set of probe ratios for each sample into a decision tree matrix;
determining, by the computing system using the decision tree matrix, an HBA genotype for each sample based on the second set of probe ratios for each sample and copy number calling thresholds for sample probe/reference probe ratios associated with each probe of the plurality of probes;
determining, by the computing system, one or more particular copy number variations are assigned to one or more samples of the plurality of samples based on the HBA genotype determined for each of the one or more samples; and
performing a confirmation test by multiplex assay methodology and gel electrophoresis or Sanger sequencing for a subset of samples, wherein each sample in the subset of samples is determined to have the one or more particular copy number variations.

### Claim 2 (depends on 1)

The computer-implemented method of claim 1, wherein the calculating the first set of probe ratios comprises: (i) comparing control probe peak heights, or signals, in each sample of the plurality of samples to corresponding control probe peak heights, or signals, in the reference sample, (ii) calculating variability in signals between the control probe peak heights, or signals, in each sample and the corresponding control probe peak heights, or signals, in the reference sample as a control probe standard deviation, (iii) determining a sample of the plurality of samples fails when any variability metrics are greater than a predetermined threshold, (iv) determining a sample of the plurality of samples does not fail when none of the variability metrics are greater than the predetermined threshold, and (v) for each sample that does not fail, comparing test probe peak heights, or signals, in the sample to corresponding test probe peak heights in the reference sample, and calculating a probe ratio between the test probe peak heights, or signals, in the sample and the corresponding test probe peak heights, or signals, in the reference sample.

### Claim 3 (depends on 2)

The computer-implemented method of claim 2, wherein the calculating the second set of probe ratios comprises: (i) comparing the control probe peak heights, or signals, in each sample of the plurality of samples to corresponding control probe peak heights, or signals, in the synthetic reference sample, (ii) calculating variability in signals between the control probe peak heights, or signals, in each sample and the corresponding control probe peak heights, or signals in the synthetic reference sample as a control probe standard deviation, (iii) determining a sample of the plurality of samples fails when any variability metrics are greater than the predetermined threshold, (iv) determining a sample of the plurality of samples does not fail when none of the variability metrics are greater than the predetermined threshold, and (v) for each sample that does not fail, comparing test probe peak heights, or signals, in the sample to corresponding test probe peak heights in the synthetic reference sample, and calculating a probe ratio between the test probe peak heights, or signals, in the sample and the corresponding test probe peak heights, or signals, in the synthetic reference sample.

### Claim 4 (depends on 3)

The computer-implemented method of claim 3, wherein the determining the HBA genotype for each sample comprises: (i) determining aberrant probe ratio patterns for each sample based on the second set of probe ratios for each sample and the copy number calling thresholds for the sample probe/reference probe ratios associated with each probe of the plurality of probes, and (ii) identify the HBA genotype for each sample based on the aberrant probe ratio patterns.

### Claim 5 (depends on 4)

The computer-implemented method of claim 4, wherein the determining the aberrant probe ratio patterns and the identifying the HBA genotype for each sample comprises:
classifying each sample as normal, having a copy number variation (CNV), or as polymorphic based on the aberrant probe ratio patterns; and
sub classifying any sample classified as having the CNV as a large targeted deletion, duplication or ‘other’ based on the aberrant probe ratio patterns.

### Claim 6 (depends on 5)

The computer-implemented method of claim 5, wherein the determining the aberrant probe ratio patterns and the identifying the HBA genotype for each sample further comprises:
sub classifying any sample classified as having the large targeted deletion as a large heterozygous deletion or a homozygous deletion;
sub classifying any sample classified as the large heterozygous deletion or the homozygous deletion for one or more of the following deletions: SEA, FIL/THAI, MED or α20.5 based on the aberrant probe ratio patterns;
sub classifying any sample classified as having the large heterozygous deletion for one or more of the following: α3.7 deletions, α4.2 deletions and/or α3.7 duplications based on the aberrant probe ratio patterns; or
sub classifying any sample classified as ‘other’ as having α3.7 deletions, α4.2 deletions, and/or α3.7 duplications based on the aberrant probe ratio patterns.

### Claim 7 (depends on 1)

The computer-implemented method of claim 1, wherein the performing the HBA assay comprises:
obtaining a pool of oligonucleotides, wherein the pool of oligonucleotides targets regions comprising an α-globin gene cluster region;
hybridizing the nucleic acid with the pool of oligonucleotides or a derivative thereof to obtain a plurality of probes for each sample of the plurality of samples; and
resolving the plurality of probes for each sample of the plurality of samples by capillary electrophoresis to obtain raw data, wherein the raw data comprises HBA copy number data for the plurality of probes.

### Claim 8 (depends on 7)

The computer-implemented method of claim 7, wherein the performing the HBA assay further comprises:
hybridizing a primer of each oligonucleotide of the pool of oligonucleotides to the nucleic acid from the plurality of samples;
ligating the hybridized oligonucleotides to the nucleic acid to obtain the plurality of probes; and
amplifying the ligated probes to obtain the raw data.